Emisphere Technologies (OTCMKTS:EMIS) and Forty Seven (NASDAQ:FTSV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Institutional and Insider Ownership
0.0% of Emisphere Technologies shares are owned by institutional investors. Comparatively, 54.3% of Forty Seven shares are owned by institutional investors. 72.9% of Emisphere Technologies shares are owned by company insiders. Comparatively, 37.4% of Forty Seven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Emisphere Technologies and Forty Seven’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Emisphere Technologies||$1.20 million||365.45||-$10.04 million||N/A||N/A|
|Forty Seven||N/A||N/A||-$70.37 million||($3.75)||-3.75|
Emisphere Technologies has higher revenue and earnings than Forty Seven.
Volatility and Risk
Emisphere Technologies has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Forty Seven has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500.
This table compares Emisphere Technologies and Forty Seven’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Emisphere Technologies and Forty Seven, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Forty Seven has a consensus price target of $24.71, indicating a potential upside of 75.65%. Given Forty Seven’s higher possible upside, analysts plainly believe Forty Seven is more favorable than Emisphere Technologies.
Emisphere Technologies beats Forty Seven on 5 of the 9 factors compared between the two stocks.
About Emisphere Technologies
Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.
About Forty Seven
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Receive News & Ratings for Emisphere Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emisphere Technologies and related companies with MarketBeat.com's FREE daily email newsletter.